Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide

Journal of Neuro-Oncology

Volumn 100, Issue 3, 2010, Pages 439-441

  Kaloshi, Gentian ^a   Sierra Del Rio, Monica ^a   Ducray, François ^a   Psimaras, Dimitri ^a   Idbaih, Ahmed ^a   Laigle Donadey, Florence ^a   Taillibert, Sophie ^a   Houillier, Caroline ^a   Dehais, Caroline ^a   Omuro, Antonio ^a   Sanson, Marc ^a   Delattre, Jean Yves ^a   Hoang Xuan, Khe ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Low grade glioma; Nitrosourea; Radiotherapy; Temozolomide

Indexed keywords

CARMUSTINE; ETOPOSIDE; LOMUSTINE; PLATINUM COMPLEX; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GLIOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NITROSOUREA COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78449277662     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0197-6     Document Type: Article

References (7)

1. M Brada L Viviers C Abson, et al. 2003 Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas Ann Oncol 14 1715 1721 1:STN:280:DC%2BD3srltVWgsg%3D%3D 10.1093/annonc/mdg371 14630674
2. K Hoang-Xuan L Capelle M Kujas, et al. 2004 Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions J Clin Oncol 22 3133 3138 1:CAS:528:DC%2BD2cXpsVGrs7o%3D 10.1200/JCO.2004.10.169 15284265
3. G Kaloshi A Benouaich-Amiel F Diakite, et al. 2007 Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome Neurology 68 21 1831 1836 1:CAS:528:DC%2BD2sXltl2itrc%3D 10.1212/01.wnl. 0000262034.26310.a2 17515545
4. JC Buckner D Gesme Jr JR O'Fallon, et al. 2003 Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities J Clin Oncol 21 251 255 1:CAS:528:DC%2BD2cXpsVWqs7w%3D 10.1200/JCO.2003.06.023 12525516
5. MJ Van den Bent JM Kros JJ Heimans, et al. 1998 Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group Neurology 51 4 1140 1145 9781544
6. JG Cairncross K Ueki MC Zlatescu, et al. 1998 Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 1473 1479 1:STN:280: DyaK1cvkslejug%3D%3D 10.1093/jnci/90.19.1473 9776413
7. MC Kouwenhoven JM Kros PJ French, et al. 2006 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment Eur J Cancer 42 2499 2503 1:CAS:528:DC%2BD28XhtVagtrfM 10.1016/j.ejca.2006.05.021 16914310